key: cord-0976586-hg9ifz7c
authors: Ferreiro-Iglesias, Rocío; Hernández-Camba, Alejandro; Labajos, Ruth Serrano; Rodríguez-Lago, Iago; Zabana, Yamile; Acosta, Manuel Barreiro-de
title: SARS-CoV-2 vaccine acceptance among gastroenterologists and inflammatory bowel disease patients: VACUNEII project
date: 2021-08-25
journal: Gastroenterol Hepatol
DOI: 10.1016/j.gastrohep.2021.08.004
sha: 1942e33488d2b62d485346fabd63f46b9f11a679
doc_id: 976586
cord_uid: hg9ifz7c

Introduction: Several vaccines against SARS-CoV-2 are currently in use and are recommended in inflammatory bowel disease (IBD) patients. Data are scarce about the gastroenterologists and IBD patient’s acceptance of SARS-CoV-2 vaccines. The aim of the study was to evaluate the intention to get vaccination with SARS-CoV-2 vaccine among IBD patients from gastroenterologists and patient’s perspective. Methods: An online anonymous survey was sent to 8000 patients from ACCU-Spain and 1000 members of the GETECCU. Three invitations were sent between October-December 2020. Descriptive analyses were performed, comparing physicians and patients responses by standard statistical analyses. Results: 144 gastroenterologists [63% female, mean age 43 years (SD 9.5)], and 1302 patients [72% female, mean age 43 years (SD 12)] responded to the survey. 95% of the physicians recommended SARS-CoV-2 vaccine for IBD patients and 87% consider that their vaccination strategies has not changed after the pandemic compared to 12% who considered that they currently refer more patients to vaccination. Regarding to IBD patients, only 43% of patients were willing to receive the vaccine and 43% were not sure. Male sex (p<0.001) and mesalazine treatment (p=0.021) were positively associated with SARS-CoV-2 vaccine acceptance. After multivariate analysis, only male sex was significantly associated with vaccination intent (OR=1.6; 95% confidence interval=1.2-2.0; p=0.001). Conclusions: Gastroenterologists and patient’s perspective about SARS-CoV-2 are different. Future efforts to increase COVID-19 vaccine and decrease unfounded beliefs among IBD patients are needed.

Methods: An online anonymous survey was sent to 8000 patients from ACCU-Spain and 1000 members of the GETECCU. Three invitations were sent between October-December 2020. Descriptive analyses were performed, comparing physicians and patients responses by standard statistical analyses.

Results: 144 gastroenterologists [63% female, mean age 43 years (SD 9.5)], and 1302 patients [72% female, mean age 43 years (SD 12)] responded to the survey. 95% of the physicians recommended SARS-CoV-2 vaccine for IBD patients and 87% consider that their vaccination strategies has not changed after the pandemic compared to 12% who considered that they currently refer more patients to vaccination. Regarding to IBD patients, only 43% of patients were willing to receive the vaccine and 43% were not sure. Male sex (p<0.001) and mesalazine treatment (p=0.021) were positively associated with SARS-CoV-2 vaccine acceptance. After multivariate analysis, only male sex was significantly associated with vaccination intent (OR=1.6; 95% confidence interval=1.2-2.0; p=0.001).

Conclusions: Gastroenterologists and patient's perspective about SARS-CoV-2 are different. Future efforts to increase COVID-19 vaccine and decrease unfounded beliefs among IBD patients are needed.

Introducción: Diferentes vacunas frente a SARS-CoV-2 están actualmente en el mercado y se recomiendan en pacientes con Enfermedad Inflamatoria Intestinal (EII).

No tenemos suficiente evidencia sobre la aceptación de este tipo de vacunas. El objetivo del estudio fue evaluar la aceptación de la vacuna frente a SARS-CoV-2 por parte de gastroenterólogos y pacientes con EII.

Métodos: Se realizó una encuesta online a 8000 pacientes de ACCU-España y 1000 miembros de GETECCU. Se enviaron tres invitaciones entre Octubre-Diciembre 2020.

Se realizó un análisis descriptivo, comparando las respuestas de médicos y pacientes .

Resultados: 144 gastroenterólogos [63% mujeres, edad media 43 años (DE 9,5)], y1302 pacientes [72% mujeres, edad media 43 años (DE 12)] respondieron a la encuesta. 95% de los médicos recomendaban la vacuna frente a SARS-CoV-2 en pacientes con EII, 87% consideraron que su estrategia de vacunación frente a diferentes vacunas no había cambiado tras la pandemia frente al 12% que consideraban que actualmente remitían más pacientes a vacunación. En cuanto a los pacientes con EII, sólo 43% aceptaban la vacunación frente a SARS-CoV-2, frente a 43% que no estaban seguros. El sexo masculino (p<0,001) y el uso de mesalazina (p=0,021) se asoció de forma positiva con la aceptación de la vacuna. En el análisis multivariante, sólo el sexo masculino fue asociado significativamente con la intención de vacunarse (OR=1,6; 95% IC=1,2-2,0; p=0,001).

Conclusiones: La perspectiva de gastroenterólogos y pacientes con EII con respecto a la vacunación frente a SARS-CoV-2 es diferente. Esfuerzos para incrementar el uso de la vacuna y disminuir falsas creencias son necesarios.

The emergence of the SARS-CoV-2 pandemic has triggered a public health crisis with a tremendous impact in our societies and the whole healthcare assistance. The recent development of vaccines against this microorganism and the implementation of mass vaccination programs could be a great opportunity for controlling viral transmission (1) (2) . Several vaccines against SARS-CoV-2 are already available and are recommended for the whole population (3) . Recent evidence has demonstrated that patients with inflammatory bowel disease (IBD) have the same risk of suffering COVID-19 as their background population (4), and international experts recommend the vaccination of these patients according to national guidelines (1). However, vaccine hesitancy by patients and caregivers can have a big impact in the course of the illness. There is still scarce data about the gastroenterologist and IBD patients' acceptance of those vaccines. The aim of this study was to evaluate the intention to get vaccinated with SARS-CoV-2 vaccine among patients with IBD and correlate it with the gastroenterologists and patients' perspective.

A collaborative study between the Spanish IBD Working Group (GETECCU) and the national patient association (ACCU Spain) which included two separate online surveys was performed. One survey was specifically designed for addressing IBD patients' In the majority of surveys performed among the general population, the acceptance rates of SARS-CoV-2 vaccination have been described to be over 70% (5) (6) . However, our study suggests a lower vaccination intent among IBD patients, with only 43% of patients willing to receive this vaccination. This is in contrast with the severity of the infection, death rate and social disruption secondary to the COVID-19 pandemic.

However, this is in line with previous reports on the low adherence to the current general vaccine recommendations in IBD (7). Recently, Dalal et al. showed high rates (80%) of SARS-CoV-2 vaccination intent among IBD patients in the USA (8). These authors also observed that white patients, those aged ≥50 years, with higher degree of education, reporting prior COVID-19 infection, and those under biologic therapy were more likely to have vaccination intent. Importantly, those patients reporting hesitancy towards vaccination were mainly related to safety concerns. It is possible that this high J o u r n a l P r e -p r o o f rate was overestimated because a short study period. In contrast, we have observed that male participants were more likely to accept the vaccine. These differences may have been also influenced by the differences between both healthcare systems and the time when the study was performed, as this survey was carried out before the start of the national vaccination programme over a period of uncertainty regarding the rapid development and approval of the first available vaccines.

Our results show that despite more physicians encourage their patients to get vaccinated and this proportion is even higher since the onset of the pandemic, many patients are still hesitant to receive the SARS-CoV-2 vaccine. Moreover, women were more likely to believe that influenza or pneumococcal vaccine may prevent SARS-CoV-2 infection. These false beliefs may have a relevant negative impact on the vaccination intent. The importance of correct awareness of IBD patients to get vaccinated is expected to reduce considerably the morbidity and mortality related to SARS-CoV-2 (9). Therefore, the current recommendations to the general population apply to patients with this condition. This survey has some limitations that should be addressed. First, the inclusion of patients and physicians only from active members of their respective societies may be not representative of the entire IBD population as participants could be members with a higher adherence to the vaccination guidelines. Moreover, this survey was performed weeks before a vaccine was available, so the reasons to their behavior were not well explored. However, some strengths of the current study should be emphasized including that, to our knowledge, this is the largest survey published in IBD patients about the acceptance of this vaccination. In addition, our findings are supported by their wide perspective on this topic as both physician and patients' perspective were included.

In summary, gastroenterologists and patients' perspectives about SARS-CoV-2 are different. Future efforts to increase SARS-CoV-2 vaccine confidence and awareness, J o u r n a l P r e -p r o o f improvement of its acceptance and decrease misinformation and unfounded beliefs are needed to ensure high compliance rates among IBD patients. 

SARS-CoV-2 vaccination for patients with inflammatory bowel diseases: recommendations from an international consensus meeting

SARS-CoV-2 vaccination for patients with inflammatory bowel disease: a British Society of Gastroenterology and IBD Clinical Research Group position statement

ECCO guidelines on the prevention, diagnosis, and management of infections in inflammatory bowel disease

patients with inflammatory bowel diseases

A global survey of potential acceptance of a COVID-19 vaccine

COVID-19 vaccine hesitancy worldwide: a concise systematic review of vaccine acceptance rates